Stopping Jardiance: What Changes and What the Studies Show
Start with the reason you take it
Jardiance (empagliflozin) may be prescribed for diabetes, heart failure, chronic kidney disease (CKD), or overlapping conditions. Before discussing a stop, write down each reason it was prescribed. A replacement that lowers glucose may not address the heart or kidney reason for treatment.
Also identify what prompted the discussion: an upcoming operation, illness, a side effect, pregnancy planning, cost, or a change in treatment goals. These situations require different decisions. If affordability threatens your next refill, contact the prescriber or pharmacist before a planned interruption; ask about available access options and alternatives. Do not increase insulin or a loop diuretic yourself. [6]
What withdrawal research actually measured
The strongest stopping evidence comes from different study settings. Their findings should not be treated as competing estimates of the same risk.
| Evidence | What happened | What it means for a stopping discussion |
|---|---|---|
| Heart failure: blinded withdrawal [2] | After roughly 30 days off treatment, cardiovascular death or HF admission occurred in 49/3,418 people originally assigned empagliflozin versus 40/3,381 assigned placebo; HR 1.18 (95% CI 0.78–1.80). | Both groups stopped their assigned treatment. The interval crosses 1; this comparison does not establish an increase in events. |
| CKD: active treatment [3] | Among 6,609 adults, kidney progression or cardiovascular death occurred in 13.1% versus 16.9% over a median two years; HR 0.72 (95% CI 0.64–0.82). | This 28% relative reduction concerns treatment, not a calculator for risk after cessation or a mortality-only benefit. |
| CKD: posttrial follow-up [4] | 4,891 participants entered two additional years without supplied trial drug. Open-label SGLT2 use was 43% versus 40%. Combined-period HR was 0.79; posttrial-only HR was 0.87. | Authors found additional benefit up to 12 months after cessation. Protection did not necessarily vanish immediately, but observational follow-up with open-label use cannot establish that planned stopping equals continuing. |
These studies followed different populations for different periods. Neither supplies a universal stopping schedule.
Safety can change the immediate decision
The US label advises withholding Jardiance at least three days, if possible, before surgery or prolonged fasting. Restart depends on clinical stability and resumed oral intake, with ketoacidosis resolved if present. A fixed postoperative countdown misses those conditions. [1]
Nausea, vomiting, abdominal pain, malaise, or shortness of breath warrant urgent assessment for possible ketoacidosis regardless of glucose. If suspected, stop Jardiance and seek care rather than waiting for a home ketone threshold or replacement prescription. [1]
For CKD, KDIGO recommends SGLT2 treatment in type 2 diabetes with eGFR at least 20. Once started, continuation below 20 can be reasonable unless intolerable or kidney replacement therapy begins. Withholding during prolonged fasting, surgery, or critical illness can be reasonable. [5]
Tell the prescriber about insulin use, kidney disease, diuretics, and recent illness with reduced food or fluid intake. These details affect the review. Jardiance is not used to manage type 1 diabetes. [1,6]
Bring a personal record, not a borrowed protocol
Use this short record to make the appointment specific:
- Treatment: current dose, prescribing clinician, and diabetes, HF, or CKD indications.
- Decision: proposed last-dose date, reason, and whether the interruption is temporary or permanent.
- Observations: actual glucose readings, weight and blood-pressure patterns, symptoms, and their dates.
- Questions: which observations matter for you, whether laboratory testing is needed, and who will interpret results.
- Next contact: whom to call, when follow-up will occur, and who decides about restarting or replacement.
Ask for clear instructions about worsening symptoms. Sudden swelling or worsening breathlessness needs prompt care. Research on intravenous furosemide in hospitalized acute HF does not provide a home dose-adjustment rule after stopping Jardiance. [2,7]
Frequently asked questions
Do I need to taper empagliflozin (Jardiance) before stopping?
The prescribing instructions give no taper schedule. Plan routine discontinuation with the prescriber around its reason and any replacement needs. [1,6]
How long does empagliflozin stay in your system after the last dose?
Its half-life is about 12.4 hours, but effects outlast blood levels. Glucosuria lasts around three days; prolonged glucosuria or ketoacidosis has been reported beyond six days, sometimes two weeks. [1]
Can stopping Jardiance cause diabetic ketoacidosis?
Symptoms of ketoacidosis need urgent assessment even without markedly high glucose. The last dose does not define a reliable safety cutoff. [1,6]
Will my blood sugar go up when I stop Jardiance?
It may rise as the glucose-lowering effect wears off. No reliable universal increase applies. Record actual readings and ask whether your diabetes treatment or monitoring needs adjustment. [6]
How long before surgery should I stop empagliflozin?
The patient guidance advises discussing a hold of at least three days before surgery. Confirm the last-dose date and fasting instructions with the surgical team. [6]
What medications can replace Jardiance if I have to stop permanently?
There is no single replacement for every indication. Ask which alternative addresses your glucose, HF, or CKD needs and whether the stopping reason also affects suitability of another SGLT2 inhibitor. [1,5,6]
Is it safe to stop Jardiance if I was taking it for heart failure?
Heart-failure symptoms and laboratory measures worsened after withdrawal in the study. That finding supports an individualized review; it does not provide a home diuretic-adjustment rule. [2]
Can I stop Jardiance if I am pregnant or trying to conceive?
Contact the prescriber promptly if you are pregnant or planning pregnancy so treatment can be reassessed. The label warns against use during the second and third trimesters. [1,6]
What blood tests should I get after stopping empagliflozin?
Testing depends on your indication and clinical situation. Discuss glucose or HbA1c monitoring and whether kidney-function or electrolyte checks are appropriate. Mandatory tests at four, eight, and twelve weeks aren't established. [5,6]
Does stopping Jardiance affect blood pressure?
Blood pressure can change after withdrawal. Record actual readings and symptoms before reviewing any treatment adjustment; a study average cannot predict your change. [2,6]
Can I restart Jardiance after surgery?
Restart depends on clinical stability, resumed oral intake and resolution of any ketoacidosis. After illness, infection or kidney injury, the reason for interruption also needs review. [1]
What is the difference between stopping Jardiance for diabetes versus for CKD?
The diabetes plan considers glucose management; the CKD plan also considers kidney protection. Posttrial kidney findings do not establish that stopping provides the same outcome as continued treatment. [3,4,5]
Will I gain weight after stopping Jardiance?
Weight may change, but weight loss is not guaranteed to persist or reverse by a fixed amount. Record the trend; sudden swelling or worsening breathlessness needs prompt assessment. [2,6]
References
Sources checked October 14, 2026.
- DailyMed. JARDIANCE—empagliflozin tablet, film coated; Cardinal Health repackaged label. Updated February 17, 2026; prescribing information revised January 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5777b8a8-ada6-4950-8548-43a1de11f075
- Packer et al. Blinded withdrawal of long-term empagliflozin treatment in heart failure. Circulation, 2023. https://pubmed.ncbi.nlm.nih.gov/37621153/
- EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine, 2023. https://pubmed.ncbi.nlm.nih.gov/36331190/
- EMPA-KIDNEY Collaborative Group. Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease. Published online 2024; New England Journal of Medicine issue, 2025. https://pubmed.ncbi.nlm.nih.gov/39453837/
- KDIGO. 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: Executive Summary. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2024-CKD-Guideline-Executive-Summary.pdf
- MedlinePlus. Empagliflozin: Drug Information. https://medlineplus.gov/druginfo/meds/a614043.html
- Felker et al. Diuretic Strategies in Patients with Acute Decompensated Heart Failure (DOSE). New England Journal of Medicine, 2011. https://pubmed.ncbi.nlm.nih.gov/21366472/
